Xenleta Now Available for Community-Acquired Bacterial Pneumonia
The oral and IV formulations of Xenleta (lefamulin), a first-in-class pleuromutilin antibiotic, have been made available in the US by Nabriva Therapeutics.
Diagnosis & Disease Information
FDA Approves First-In-Class Antibiotic to Treat Community-Acquired Bacterial Pneumonia
The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Poor Pneumonia Outcomes Tied to Overuse of Broad-Spectrum Antibiotics
Poor outcomes include higher mortality, longer hospital stay, and greater risk for C. difficile infection
Baxdela Gets FDA’s Priority Review for Community-Acquired Bacterial Pneumonia
The sNDA is supported by data from the phase 3, double blind, DEFINE-CABP trial (N=860) which compared the safety and efficacy of Baxdela to moxifloxacin for the treatment of CABP.
Treatment Options for Methicillin-Resistant Staphylococcus Aureus Pneumonia Evaluated
Evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with trimethoprim-sulfamethoxazole (TMP-SMX), clindamycin, doxycycline, or minocycline was found to be based on limited data, according to a systematic review published in the Annals of Pharmacotherapy. Currently, the Infectious Disease Society of America (IDSA) recommends vancomycin and linezolid for the treatment of MRSA pneumonia, although…
Zerbaxa Approved to Treat Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
The FDA has expanded the approval of Zerbaxa (ceftolozane and tazobactam; Merck) to include treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients ≥18 years old.
Decreasing Ventilator-Associated Pneumonia in Level I Trauma Patients
Performing therapeutic bronchoscopy at the time of intensive care unit admission may decrease ventilator-associated pneumonia incidence in patients with level I trauma.
Idiopathic Pulmonary Fibrosis Outcomes Similar With Pneumonia or Acute Exacerbation
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
AEDs Tied to Higher Pneumonia Risk in Alzheimer Patients
Risk for pneumonia highest within first month of antiepileptic drug use but persists through two years
Pneumococcal Vaccination at Age 50 Prevents the Most Disease
But cost of giving pneumococcal vaccines to all 50-year-olds exceeds $250,000 per QALY
